ATCC 35218 and Klebsiella pneumoniae ATCC 700603 were used as control strains. The results were interpreted as per the CLSI (formerly NCCLS) criteria, except for ceftriaxone/sulbactam. Because there are no published breakpoints for the latter combination, the susceptibility criterion used for this combination was .8 mm increase in zone diameter of ceftriaxone/sulbactam in comparison with that of ceftriaxone alone. Phenotypic ESBL detection by disc synergy tests was performed on all 54 isolates using co-amoxiclav and piperacillin/tazobactam discs as a source of inhibitors. Briefly, the test inoculum (equivalent in turbidity to that of a 0.5 McFarland standard) was streaked on MuellerHinton agar. Discs of co-amoxiclav (20/10 mg) or piperacillin/ tazobactam were placed 20 and 30 mm, centre to centre, from discs containing cefotaxime (30 mg), ceftazidime (30 mg) and cefpirome (30 mg) and plates were incubated at 378C overnight. Enhancements of zones of inhibition of cephalosporins towards piperacillin/tazobactam or co-amoxiclav were considered as positive ESBL results. All tests were performed in duplicate.
In disc synergy tests, none of the 54 ESBL producers was detected when co-amoxiclav discs were placed 30 mm from cephalosporin discs, and only 4 isolates (7.4%) were detected when this was reduced to 20 mm. It is known that optimal disc placement is an important issue in such tests. 6 However, when piperacillin/tazobactam discs were used and the discs were placed 20 mm apart, we readily detected most ESBL-producing isolates; synergy with ceftriaxone, cefotaxime and ceftazidime allowed detection of 92.6% (50/54), 90.7% (49/54) and 74.1% (40/54) of ESBL producers, respectively. When the discs were placed at 30 mm, ESBL could still be detected in all the isolates; most (88.9% with ceftriaxone and 83.3% with cefotaxime) of the isolates still giving excellent synergistic patterns. On the basis of these findings, we feel that piperacillin/ tazobactam (or tazobactam alone) could be a better indicator when combined with ceftriaxone and cefotaxime for the phenotypic detection of ESBLs, especially in CTX-M producers. This needs to be evaluated further and also against other classes of b-lactamases.
To conclude, ceftriaxone/sulbactam proved to be effective in vitro against 54 diverse CTX-M-15-producing E. coli strains. This novel combination merits further investigation, as does the use of piperacillin/tazobactam discs for the phenotypic detection of ESBLs.
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None to declare. nil. In addition, emerging fluconazole resistance has been reported in species typically susceptible to this agent, such as C. albicans. 1 The echinocandins have a different target from that of azoles, with potential both for additive effects with azoles and for activity against azole-resistant fungi. 2 Micafungin is a new echinocandin with excellent in vitro and in vivo activities against Candida spp.
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In this study, we hypothesized that the combination of fluconazole with micafungin could be advantageous over each monotherapy against Candida spp. and as the mechanisms of action of both drugs are different, antagonism might not be expected. Moreover, the use of antifungal combinations permits smaller doses, shorter duration of therapy and a wider spectrum of activity.
2 Synergistic interactions between fluconazole and micafungin have already been observed in previous in vitro studies on Cryptococcus spp. and other basidiomycetous yeasts. 3, 4 A total of 105 clinical isolates were tested (15 C. albicans, 20 Candida dubliniensis, 15 C. glabrata, 20 C. krusei, 10 Candida lusitaniae, 10 Candida parapsilosis and 15 Candida tropicalis). The isolates were subcultured on Sabouraud dextrose agar plates and incubated at 358C for 24 h. Yeasts suspensions were adjusted to 1-5 Â 10 6 cfu/mL by counting with a haemocytometer. Micafungin (Astellas Pharma Inc., Tokyo, Japan) and fluconazole (Pfizer Inc., Madrid, Spain) were obtained as pure powders and diluted in sterile distilled water. Drug interactions were assessed by the chequerboard microdilution method [according to the CLSI (formerly NCCLS) M27-A2 document] and included the MIC determinations of each drug alone. 5 The MIC was defined as the lowest concentration that produced 50% growth inhibition (MIC-2). The temperature of incubation was 358C, and MIC readings were recorded after 48 h. The fractional inhibitory concentration index (FICI) was used to classify drug interaction ( 0.5, synergistic; .0.5 and 4, indifferent and .4, antagonistic). 6 FICI is the sum of the FIC of each of the drugs, which in turn is defined as the MIC of each drug when it is used in combination divided by the MIC of the drug when it is used alone.
Mean geometric MICs of drugs alone and in combinations are shown in Table 1 . MICs of both drugs alone agree with those obtained by other authors. 7, 8 Although MICs of both drugs in combination were generally lower here than those observed when the drugs were tested alone, indifference was observed in most cases. The MICs of fluconazole when combined were significantly lower than when alone for C. krusei and C. glabrata (P , 0.0105 and P , 0.0001, respectively), but not for the rest of the species. The MICs of micafungin when combined were significantly lower than when alone for C. albicans, C. krusei, C. glabrata and C. lusitaniae (P , 0.0032, P , 0.0267, P , 0.0001 and P , 0.0232, respectively). Synergistic interactions occurred against 33%, 26% and 7% of isolates of C. albicans, C. tropicalis and C. glabrata, respectively, in all cases, the FICI being ,0.5. In the cases of synergism, fluconazole MICs changed from susceptible to more susceptible, with a few exceptions which changed from susceptible dose-dependent to susceptible, and micafungin MICs changed from susceptible to more susceptible. Micafungin shows a lower activity against C. parapsilosis, as has been previously observed by other authors. 7 In our study, micafungin showed high MICs which tended to drop Correspondence when this drug was combined with fluconazole. This combination could be of interest in those cases where the isolates of this species show high MICs of fluconazole. In spite of the predominance of indifferent interactions, which agrees with the results provided by other authors, 2,9 the lack of antagonism and the percentages of synergism obtained against C. albicans and C. tropicalis are interesting issues. Although scarce in vivo data on the activity of this combination are available, it has been demonstrated that it was able to prolong survival and to reduce tissue burden in murine models of C. glabrata infection and in trichosporonosis. 10, 11 Therefore, combination of these agents may warrant future clinical evaluation in Candida infections.
